Bicycle Therapeutics plc Discloses Development Strategy Leveraging NECTIN4 Gene Amplification

On December 13, 2024, Bicycle Therapeutics plc, a company specializing in developing therapeutic solutions based on its proprietary bicyclic peptide technology, revealed significant data updates across its zelenectide pevedotin program. These updates, coupled with innovative development strategies leveraging NECTIN4 gene amplification, stand to reshape the landscape of cancer treatment. The company unveiled these advancements through a press release issued on December 12, 2024, and further discussed the updates in a conference call and webcast held on December 13, 2024.

The key revelations from the data updates encompassed various fronts:

In the realm of oncology, zelenectide pevedotin exhibited a robust 60% overall response rate when combined with pembrolizumab in uncharted territory—first-line metastatic urothelial cancer patients who are ineligible for cisplatin treatment. This response rate, consistent with other available therapies, showed potential for zelenectide pevedotin to tip the scales in treating such patients.

Moreover, the company shared dose selection insights and outlined plans for the Phase 2/3 Duravelo-2 trial slated for the second half of 2025. The trial aims to delve deeper into the efficacy of zelenectide pevedotin in treating metastatic urothelial cancer patients.

A particularly encouraging highlight emerged when examining heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification. Zelenectide pevedotin showcased enhanced responsiveness in this subgroup, offering a glimmer of hope for those who face challenges with existing treatments. Harnessing the potential of this gene amplification, Bicycle Therapeutics aims to drive development forward, targeting a plethora of cancers beyond bladder cancer.

CEO Kevin Lee expressed optimism, stating that the data presented reaffirmed zelenectide pevedotin’s potential in addressing Nectin-4 associated cancers. He emphasized the company’s dedication to expedite the development process, including plans to initiate Phase 1/2 trials for zelenectide pevedotin in various cancers during the upcoming year.

The event also featured an esteemed panel of oncology experts who delved into the updates, shedding light on the promising advancements and their implications for cancer treatment.

Bicycle Therapeutics remains committed to spearheading the charge in revolutionizing cancer therapy through its groundbreaking research and innovative treatment approaches.

The complete press release issued by Bicycle Therapeutics can be accessed for further detailed information.

-END-

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bicycle Therapeutics’s 8K filing here.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.